DexCom, Inc. (DXCM)

Over the past six months, DexCom's stock price has been impacted by several events. DexCom reported strong first-quarter 2026 financial results, with revenue growing 15% year-over-year and raised its full-year 2026 guidance for non-GAAP operating and adjusted EBITDA margins. Wells Fargo lowered its price target for DXCM from $93 to $85, while Mizuho raised its price target from $78 to $90, and Citi lowered its price target to $79 from $84. DexCom announced an upcoming Investor Day on May 14, 2026, and appointed Rick Osterloh to its Board of Directors on February 26, 2026. The stock has experienced some pressure, being down approximately 4.51% in the 30 days leading up to May 6, 2026, and there have been public announcements regarding stockholder investigations and class action lawsuits.

DexCom's products and services experience some demand seasonality. The company has noted "typical Q1 seasonality" in relation to its gross profit performance. Historically, the stock has shown a tendency for a "green month" in May. Overall, demand for DexCom's products continues to grow, driven by the increasing global prevalence of diabetes and the accelerating adoption of connected health tools.

DexCom, Inc. is a healthcare company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. The company's core business revolves around devices that provide real-time glucose monitoring, primarily for people with Type 1 and Type 2 diabetes. Major products include the Dexcom G7 and G6 integrated CGM systems, Dexcom Share remote monitoring system, Dexcom Real-Time API, Dexcom ONE CGM system, associated software, mobile apps, and the Stelo Glucose Biosensor. The company also provides Dexcom Care training and support services to CGM system users.

DexCom, Inc. operates internationally, with its global headquarters and R&D center located in San Diego, California, U.S. Manufacturing facilities are situated in Mesa, Arizona, U.S.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. The United States accounts for a significant portion of DexCom's net sales, representing 71.5% of the total. The company is actively expanding its international presence, with notable growth in geographies where access has recently been expanded, such as France and Canada.

DexCom has cultivated a strong brand reputation, particularly among clinicians, due to the accuracy and superior features of its products, which are recognized for leading to better health outcomes. The company is considered a leader in diabetes management. However, the company's reputation has faced some challenges in the past year with the announcement of stockholder investigations and class action lawsuits.

DexCom, Inc.'s ownership structure is a mix of institutional, retail, and individual investors. Institutional investors and hedge funds hold a significant majority, owning 97.75% of the company's stock. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., State Street Corp, Baillie Gifford & Co, Geode Capital Management, Llc, Alliancebernstein L.p., UBS Asset Management Americas Inc, Norges Bank, Jpmorgan Chase & Co, and Jennison Associates Llc. Retail and individual investors also hold a portion of the company's shares.